Prevention & care

Macular degeneration: central vision, dry and wet AMD, stages, supplements, injections, and evidence limits

13 sources · Latest source check 2026-10-20 UTC

On this page

Age-related macular degeneration damages the macula, the retinal region responsible for sharp central vision. Type, stage and damage location matter for care.[1]

Type and stage describe different features

Type and stage describe different features
Label	Broad distinction
Early / intermediate dry AMD	Earlier stages; symptoms may be absent.[1]
Late atrophic disease / geographic atrophy	Areas of retinal degeneration; central location matters.[8]
Wet / neovascular AMD	Abnormal vessels damage the macula; classified as late AMD.[4]

Central vision and the whole visual field are different

NEI explains that AMD can impair recognizing faces, reading or close work without itself causing complete blindness. Central acuity and retained peripheral vision are distinct functions. Preserved side vision does not establish that central tasks, driving or independent reading remain safe or easy.[1]

Painless or symptom-free disease can still need assessment

The NHS describes central blur or distortion, wavy lines and possible difficulty recognizing faces. AMD may be found before symptoms and is generally not painful. The absence of redness or pain is therefore not evidence of a healthy macula; a new visual change needs its own assessment.[6]

Tests separate visual function from retinal anatomy

The NHS describes vision testing and retinal examination; NEI describes optical coherence tomography (OCT) imaging. Visual clarity and anatomy are different assessments. A glasses prescription cannot stage AMD.[7][1]

AREDS2 is a studied formulation for defined disease settings

NEI’s 2021 supplement explanation emphasizes intermediate AMD and selected fellow-eye protection when late disease is present in one eye. It does not establish prevention for people without AMD or slowing early into intermediate disease. A bottle labeled “eye health” is not automatically equivalent to the studied formulation.[2]

The ingredient families have different roles

The ingredient families have different roles
Component	Why the distinction matters
Vitamins C and E	Antioxidant ingredients in the studied combination.[2]
Lutein and zeaxanthin	Carotenoids replacing beta-carotene in AREDS2.[2]
Zinc and copper	Mineral ingredients; copper addresses zinc-related deficiency concerns.[3]

More nutrients do not automatically mean more protection

The formula uses amounts different from an ordinary multivitamin and can interact with medicines. NEI highlights lung-cancer concerns with beta-carotene in current or former smokers. Formulation, disease stage and medication review matter; this page does not supply a personal supplement dose or endorse a brand.[2]

A newer analysis measured how atrophy approached central vision

The report published online in 2024, with a 2025 issue date, reanalyzed AREDS/AREDS2 eyes with geographic atrophy. In selected noncentral disease, antioxidant or lutein/zeaxanthin assignments were associated with slower progression toward the center. Area-based growth outcomes did not show the same significant result. This is a post hoc analysis of existing trials, not independent new randomized replication or proof that every late-disease patient regains sight.[8]

The newer finding should not be silently inserted into an older leaflet

NEI’s 2021 leaflet says supplements probably do not help when both eyes already have late AMD. The newer analysis examines specific atrophy locations and endpoints. Their scopes and dates need explanation; complete contemporary guideline reconciliation and individual eligibility remain unsettled in this Atlas overview.[2][8]

Anti-VEGF medicines target abnormal vessel activity

NEI’s December 2024 explanation describes injections intended to reduce bleeding and leakage in wet AMD. Many people need repeated care; a first improvement does not establish permanent resolution. Photodynamic therapy uses a light-sensitive medicine and targeted laser activation in selected settings. This is a different mechanism from simply reshaping the cornea to correct focus.[4]

Geographic-atrophy medicines have a different target

Current US labels identify pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) as complement inhibitors for geographic atrophy secondary to AMD. These are injections administered by qualified clinicians, not nutritional formulas or the same treatment as anti-VEGF. A US indication does not establish worldwide access or select treatment for every dry-AMD stage.[10][11]

Benefits must be weighed alongside procedure and medicine risks

The Syfovre label warns about infection, retinal detachment, increased pressure, wet AMD and retinal vasculitis or vascular occlusion, including possible severe vision loss. A reassuring average trial result cannot erase a serious postmarketing signal; product-specific monitoring and prompt reporting of changes matter.[10]

Izervay’s September 2026 label also warns about injection-related infection or retinal detachment, increased pressure and neovascular AMD. Adverse-event percentages across different product trials are not a direct head-to-head safety ranking. The treatment team should explain the actual product, monitoring and benefit–harm uncertainty.[11]

Risk reduction and adapting to vision loss serve different purposes

The NHS links risk to age, family history, smoking and other health factors while describing the exact cause as unknown. Risk reduction cannot promise that established damage will reverse. This article has not independently compared every dietary pattern, exercise program or smoking-cessation effect on AMD outcomes.[5]

NEI describes low-vision devices and rehabilitation to support independence. Task adaptations address function when lost central vision persists. Rehabilitation is a meaningful care goal even if underlying retinal changes remain.[1]

Sudden worsening should not be dismissed as ordinary aging

The NHS advises urgent help for sudden deterioration, a moving dark curtain or a red painful eye, which can signal other urgent problems. Use local eye or emergency services. An existing AMD diagnosis does not make every new visual symptom an expected slow progression.[6]

An Amsler grid is a monitoring aid between visits

An Amsler grid is a square of lines with a central dot. The eye team may use it to help you notice new distortion or blank areas between appointments. The American Academy of Ophthalmology's explanation checks each eye separately with the appropriate reading correction. Ask for a demonstration and your own monitoring plan. New wavy, dark, blank or blurred areas need prompt contact with the eye team, rather than waiting for the next planned check.[12]

Evidence & uncertainty

NEI’s June 2021 “no late dry treatment” wording predates current US geographic-atrophy labels. Supplement findings also need stage-specific interpretation; newer analysis is not independent replication. Long-term comparative appraisal remains incomplete.[1][10][11][8]

Selected-source overview · Independent review pending

Published questions

Does AMD damage central vision or necessarily cause complete blindness?

Selected-source overview · Independent review pending. Read the evidence context.

Central macular function is distinct from the whole visual field.[1]

Evidence behind this answer

Age-Related Macular Degeneration (AMD)
agency condition or prevention explanation · 2021
Selected relevant original official page passages inspected · June 2021: central vision, stages, OCT and low-vision support; outdated late-dry-treatment statement identified